Last reviewed · How we verify
NCT04709120: ACTIV-2
Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
trial in Covid19 in 2,968 participants. Completed in 30 May 2021.
30 March 2021
Quick facts
| Lead sponsor | Eurasian Association of Therapists |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,968 |
| Start date | 1 October 2020 |
| Primary completion | 30 March 2021 |
| Estimated completion | 30 May 2021 |
| Sites | 1 location across Russia |
Conditions studied
- Covid19 — all drugs for Covid19 →
- Comorbidities and Coexisting Conditions — all drugs for Comorbidities and Coexisting Conditions →
- Risk Factor, Cardiovascular — all drugs for Risk Factor, Cardiovascular →
- Death — all drugs for Death →
Sponsor
Eurasian Association of Therapists
Who can join
18 and older, any sex, with Covid19 or Comorbidities and Coexisting Conditions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparison of COVID-19 disease course in hospitalized patients infected by SARS-CoV-2 in first and second waves of the novel coronavirus infection
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predicting outcomes of the acute phase of COVID-19. High sensitive prognostic model, based on the results of the international registry "analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients" (ACTIV).
Arutyunov GP, Tarlovskaya EI, Polyakov DS, Batluk TI, et al · · 2024 · PMID 38596083 · DOI 10.1016/j.heliyon.2024.e28892
Verify or expand the search:
- PubMed search for NCT04709120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Eurasian Association of Therapists trials
Trials by the same sponsor.
- NCT05690009 — Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease · completed
- NCT04295057 — Register of Therapeutical Patients Over 60 Years · unknown
- NCT05226416 — Analysis of Health Status of Сomorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 Infection · completed
- NCT05189847 — Clinical Register Studying the therApeutic Patient Population With Multifocal Atherosclerosis · completed
- NCT04492384 — Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04709120 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eurasian Association of Therapists
- Last refreshed: 8 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04709120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing